JP2010504352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504352A5 JP2010504352A5 JP2009529371A JP2009529371A JP2010504352A5 JP 2010504352 A5 JP2010504352 A5 JP 2010504352A5 JP 2009529371 A JP2009529371 A JP 2009529371A JP 2009529371 A JP2009529371 A JP 2009529371A JP 2010504352 A5 JP2010504352 A5 JP 2010504352A5
- Authority
- JP
- Japan
- Prior art keywords
- benzazepine
- phenyl
- oxospiro
- dihydro
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 46
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 2,3-dihydro-1′-methyl-2′-oxospiro {4H-1-benzazepine-4,3′-piperidine}- 1 (5H) -yl Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 5
- 102000002852 Vasopressins Human genes 0.000 claims 5
- 108010004977 Vasopressins Proteins 0.000 claims 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- 229960003726 vasopressin Drugs 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- FLGYZVSYNLBJDV-UHFFFAOYSA-N 2-spiro[1-benzazepine-4,3'-pyrrolidine]-1'-ylacetic acid Chemical compound C1N(CC(=O)O)CCC21C=C1C=CC=CC1=NC=C2 FLGYZVSYNLBJDV-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021036 Hyponatraemia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 1
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- DIFPAMJXWONROD-UHFFFAOYSA-N spiro[1-benzazepine-4,3'-pyrrolidine] Chemical compound C1NCCC21C=C1C=CC=CC1=NC=C2 DIFPAMJXWONROD-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82667106P | 2006-09-22 | 2006-09-22 | |
| PCT/US2007/078926 WO2008036759A1 (en) | 2006-09-22 | 2007-09-19 | Spiro benzazepines as vasopressin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504352A JP2010504352A (ja) | 2010-02-12 |
| JP2010504352A5 true JP2010504352A5 (enExample) | 2010-12-02 |
Family
ID=39093069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529371A Pending JP2010504352A (ja) | 2006-09-22 | 2007-09-19 | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7825111B2 (enExample) |
| EP (1) | EP2076517A1 (enExample) |
| JP (1) | JP2010504352A (enExample) |
| CN (1) | CN101541807A (enExample) |
| AU (1) | AU2007299822A1 (enExample) |
| CA (1) | CA2665851A1 (enExample) |
| WO (1) | WO2008036759A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003031407A2 (en) * | 2001-10-12 | 2003-04-17 | Serenix Pharmaceuticals, Llc | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
| WO2006102308A2 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1b antagonists |
| AR066834A1 (es) * | 2007-06-06 | 2009-09-16 | Janssen Pharmaceutica Nv | Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central. |
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| JP5968466B2 (ja) * | 2012-12-26 | 2016-08-10 | 株式会社三和化学研究所 | 新規ベンゾアゼピン誘導体及びその医薬用途 |
| TW201600522A (zh) * | 2014-02-20 | 2016-01-01 | 赫孚孟拉羅股份公司 | 螺－唑酮 |
| CN116139282A (zh) | 2014-03-28 | 2023-05-23 | 阿泽范药品公司 | 用于治疗神经退行性疾病的组合物和方法 |
| CN111212842B (zh) * | 2017-09-05 | 2022-10-25 | 布莱克索恩治疗公司 | 血管加压素受体拮抗剂以及与其相关的产品和方法 |
| JP2020534274A (ja) | 2017-09-15 | 2020-11-26 | アゼヴァン ファーマシューティカルズ，インコーポレイテッド | 脳損傷を治療するための組成物及び方法 |
| US20200337590A1 (en) | 2018-01-16 | 2020-10-29 | Bayer Aktiengesellschaft | Assistance in the treatment of cardiac insufficiency |
| CN109608411A (zh) * | 2018-12-17 | 2019-04-12 | 上海合全药物研发有限公司 | 一种叔丁基-1-氧亚基-6-氧杂-9-氮杂螺[4.5]癸烷-9-甲酸基酯的制法 |
| TW202220958A (zh) * | 2020-08-07 | 2022-06-01 | 美商卡司馬療法公司 | Ｔｒｐｍｌ調節劑 |
| CN112939864B (zh) * | 2021-01-29 | 2022-05-06 | 中国医科大学 | 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| US5985869A (en) | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| HK1003107A1 (en) | 1989-10-20 | 1998-10-09 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| CA2143117A1 (en) | 1992-10-07 | 1994-04-14 | Ben E. Evans | Tocolytic oxytocin receptor antagonists |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| FR2708606B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| IL153710A0 (en) * | 2000-07-05 | 2003-07-06 | Ortho Mcneil Pharm Inc | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| AU2002231098A1 (en) * | 2000-12-15 | 2002-06-24 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| US7011898B2 (en) * | 2003-03-21 | 2006-03-14 | Air Products And Chemicals, Inc. | Method of joining ITM materials using a partially or fully-transient liquid phase |
| AU2004252135A1 (en) | 2003-06-17 | 2005-01-06 | Janssen Pharmaceutica N.V. | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| EA011089B1 (ru) | 2003-06-17 | 2008-12-30 | Янссен Фармацевтика Н.В. | Замещённые спиробензазепины |
| WO2007084591A2 (en) | 2006-01-20 | 2007-07-26 | Janssen Pharmaceutica N.V. | Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid |
-
2007
- 2007-09-19 WO PCT/US2007/078926 patent/WO2008036759A1/en not_active Ceased
- 2007-09-19 CN CNA2007800432304A patent/CN101541807A/zh active Pending
- 2007-09-19 US US11/857,954 patent/US7825111B2/en not_active Expired - Fee Related
- 2007-09-19 JP JP2009529371A patent/JP2010504352A/ja active Pending
- 2007-09-19 EP EP07842807A patent/EP2076517A1/en not_active Withdrawn
- 2007-09-19 AU AU2007299822A patent/AU2007299822A1/en not_active Abandoned
- 2007-09-19 CA CA002665851A patent/CA2665851A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504352A5 (enExample) | ||
| JP2010504351A5 (enExample) | ||
| AU2017283769B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| AU2016276806B2 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| ES2873895T3 (es) | Compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53 | |
| JP5132673B2 (ja) | ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール | |
| JP2023530320A (ja) | Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド | |
| JPWO2018009625A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| CA2835617A1 (en) | Benzodioxane inhibitors of leukotriene production | |
| JPWO2020017587A1 (ja) | ピリダジノン誘導体 | |
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| JP2008513498A5 (enExample) | ||
| JP2005504080A5 (enExample) | ||
| JP2005508967A5 (enExample) | ||
| CN101605792A (zh) | 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途 | |
| KR20080007268A (ko) | ＨＣＶ 억제제로서 유용한 피리도[2,3-ｄ]피리미딘 및 그의제조 방법 | |
| DK2303895T3 (en) | Thiazolyl AND OXAZOLYLISOQUINOLINONER AND methods of use thereof | |
| NZ225706A (en) | 2-((4-piperidyl)methyl)-1,2,3,4-tetrahydro-9h-pyrido(3,4-b) indole derivatives and their preparation | |
| JP6386527B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロピリダジン | |
| JP2006523193A5 (enExample) | ||
| JP2022547777A (ja) | ヒダントイン誘導体 | |
| JP2016514129A (ja) | カリウムイオンチャネル阻害剤としてのフタラジン | |
| JP2004507527A5 (enExample) |